As at 31 December | |||||
GROUP | COMPANY | ||||
ASSETS | Notes | 2025 | 2024 | 2025 | 2024 |
Non-current assets | |||||
Property, plant and equipment | 5 | 737 | 897 | ||
Right-of-use assets | 6 | 174 | 342 | ||
Investments in subsidiaries | 7 | 76,046 | 91,238 | ||
Intangible assets | 8 | - | - | ||
Trade and other receivables | 11 | 9,426 | 7,054 | ||
Investments accounted for under the equity method | - | - | |||
Other assets | 12 | - | 66 | ||
Deferred income tax assets | 19 | 163 | 74 | ||
Biological assets | 9 | - | - | ||
Total non-current assets | 86,546 | 99,671 | |||
Current assets | |||||
Biological assets | 9 | - | |||
Inventories | 10 | - | - | ||
Trade and other receivables | 11 | - | 12 | ||
Other assets | 12 | 146 | 144 | ||
Cash and cash equivalents | 13 | 2 | 3 | ||
Total current assets | 148 | 159 | |||
Assets held for sale | 30 | 8,455 | - | ||
TOTAL ASSETS | 95,149 | 99,830 | |||
EQUITY AND LIABILITIES | |||||
Capital and reserves | |||||
Share capital | 15 | 67,803 | 67,803 | ||
Share premium | 15 | - | 6,707 | ||
Legal reserve | 15 | - | 2,041 | ||
Revaluation reserve | 15 | - | - | ||
Reserve for share-based payments to employees | 15 | 2,693 | 2,693 | ||
Retained earnings | ( | ( | (18,603) | (19,337) | |
Equity attributable shareholders of the Company | 51,893 | 59,907 | |||
Non-controlling interest | - | - | |||
Total equity | 51,893 | 59,907 |
Non-current liabilities | |||||
Borrowings | 16 | 5,501 | - | ||
Lease liabilities | 17 | 36 | 183 | ||
Grants | 18 | 419 | 596 | ||
Deferred income tax liabilities | 19 | - | - | ||
Other amounts payable | 16, 20, 21 | 9,830 | 6,371 | ||
15,786 | 7,150 | ||||
Total non-current liabilities | |||||
Current liabilities | |||||
Borrowings | 16 | 25,724 | 31,275 | ||
Lease liabilities | 17 | 158 | 188 | ||
Trade payables | 20 | 888 | 524 | ||
Other amounts payable | 21 | 700 | 786 | ||
Total current liabilities | 27,470 | 32,773 | |||
Liabilities directly associated with the assets held for sale | 30 | - | - | ||
Total liabilities | 43,256 | 39,923 | |||
TOTAL EQUITY AND LIABILITIES | 95,149 | 99,830 |
STATEMENT OF PROFIT OR LOSS | Year ended 31 December | |||||
GROUP | COMPANY | |||||
Continuing operations | Notes | 2025 | 2024 | 2025 | 2024 | |
Revenue | 22 | 3,321 | 3,289 | |||
Dividends from subsidiaries | 26 | - | 1,079 | |||
Cost of sales | 22, | ( | ( | - | - | |
23 | ||||||
Change in fair value of biological assets | 9, 22 | ( | ( | - | - | |
GROSS PROFIT (LOSS) | ( | 3,321 | 4,368 | |||
Selling expenses | 24 | ( | ( | (204) | (308) | |
Administrative expenses | 25 | ( | ( | (3,321) | (4,170) | |
Impairment loss of investments in subsidiaries | 7 | (6,726) | (18,696) | |||
Net impairment reversal (loss) of financial assets | ( | ( | (18) | (116) | ||
Net impairment reversal (loss) of intangible assets | ( | - | (327) | |||
Other income | 27 | 19 | 13 | |||
Other gain/(loss), net | 28 | 10 | 8 | |||
OPERATING PROFIT (LOSS) | ( | ( | (6,919) | (19,228) | ||
Finance costs | 29 | ( | ( | (1,652) | (3,609) | |
( | ( | (8,571) | (22,837) | |||
(LOSS) BEFORE INCOME TAX | ||||||
Income tax | 19 | ( | ( | 88 | 75 | |
(LOSS) FROM CONTINUING OPERATIONS | ( | ( | (8,483) | (22,762) | ||
Profit (loss) from discontinued operation (attributable to equity holders of the company) | 30 | ( | - | - | ||
NET (LOSS) FOR THE PERIOD | ( | ( | (8,483) | (22,762) | ||
NET PROFIT/(LOSS) ATTRIBUTABLE TO: | ||||||
Shareholders of the Company | ( | ( | (8,483) | (22,762) | ||
Non-controlling interest | ( | ( | - | - |
Basic and diluted earnings/(loss) per share (EUR) | |||||
31 | ( | ( | (0.04) | (0.10) | |
STATEMENT OF OTHER COMPREHENSIVE INCOME | |||||
NET PROFIT/(LOSS) FOR THE PERIOD | ( | ( | (8,483) | (22,762) | |
Other comprehensive income: | |||||
Items that will not be reclassified to profit or loss | |||||
Revaluation of land, before tax | 5 | ( | - | - | |
Deferred income tax liability on revaluation of land | 19 | ( | - | - | |
Effect of changes in tax rates | 19 | ( | ( | - | - |
Total other comprehensive income | ( | - | - | ||
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR | ( | ( | (8,483) | (22,762) | |
COMPREHENSIVE INCOME/(LOSS) ATTRIBUTABLE TO: | |||||
Shareholders of the Company | ( | ( | (8,483) | (22,762) | |
Non-controlling interest | ( | ( | - | - | |
( | ( | (8,483) | (22,762) |
Equity attributable to shareholders of the Company | |||||||||
GROUP | Equity | ||||||||
Reserve | for | attributable to | |||||||
share-based | Retained | shareholders | Non- | ||||||
Share | Revaluation payments | to Legal | earnings/ | of the | controlling | ||||
Share capital | premium | reserve | employees | reserve | (deficit) | Company | interest | Total | |
Balance at 1 January 2024 | ( | ||||||||
Comprehensive income | |||||||||
Net (loss) for the year | ( | ( | ( | ( | |||||
Other comprehensive income | - | - | - | - | - | - | - | - | - |
Revaluation of land after income tax effect (notes 5, 19) | |||||||||
Total comprehensive income | ( | ( | ( | ( | |||||
Share-based payment (note 15) | |||||||||
Transfer to reserve for share-based payments to employees (note | |||||||||
15) | ( | ||||||||
Issue of new shares (note 15) | ( | ||||||||
Balance at 31 December 2024 | ( | ||||||||
Comprehensive income | |||||||||
Net profit/(loss) for the year | ( | ( | ( | ( | |||||
Other comprehensive income | - | - | - | - | - | - | - | - | - |
Revaluation of land after income tax effect (notes 5, 19) | ( | ( | ( | ||||||
Total comprehensive income | ( | ( | ( | ( | ( | ||||
Share-based payment (note 15) | |||||||||
Coverage of losses | ( | ( | |||||||
Transfer to reserve for share-based payments to employees (note | |||||||||
15) | |||||||||
Issue of new shares (note 15) | |||||||||
Balance at 31 December 2025 | ( | ||||||||
GROUP | COMPANY | ||||
Cash flows from operating activities | Notes | 2025 | 2024 | 2025 | 2024 |
Net profit (loss) before tax from: | |||||
Continuing operations | ( | ( | (8,571) | (22,837) | |
Discontinued operations | ( | - | - | ||
Profit before tax, including discontinued operations | ( | ( | (8,571) | (22,837) | |
Non-cash expense (income) items and other adjustments | |||||
Depreciation expense (Property, plant and equipment) | 5 | 236 | 254 | ||
Depreciation expense (Right-of-use assets) | 6 | 142 | 166 | ||
Amortization expense | 8 | - | - | ||
Share-based compensation expense recognized in the income statement | 25 | 469 | 607 | ||
Write-offs of property, plant and equipment/intangible assets | 5 | - | 327 | ||
(Profit) loss on sale of property, plant and equipment | 28 | ( | ( | - | - |
Elimination of other non-cash flows | - | - | |||
Provisions for possible losses on receivables and write-offs of debts | 11 | (2) | (68) | ||
Write-off of inventories and biological assets | 23 | - | - | ||
Impairment of investments | 7 | 6,737 | 18,713 | ||
Interest income | 27 | ( | - | - | |
Finance expenses | 29 | 935 | 2,689 | ||
Interest expense related to right-of-use assets | 29 | 25 | 36 | ||
Dividends from subsidiaries | 26 | - | (1,079) | ||
(Profit) loss due to change in fair value of biological assets | 22 | - | - | ||
Amortization of grants related to assets | 18 | ( | ( | (177) | (121) |
Impairment of inventories | 10, | ( | - | - | |
Effect of discounting of debts of subsidiaries | 29 | 465 | 466 | ||
Changes in working capital | |||||
(Increase) decrease in biological assets | ( | ( | - | - | |
(Increase) decrease in trade and other receivables | ( | (2,294) | (4,247) | ||
(Increase) decrease in inventories | ( | - | 4 | ||
(Decrease) increase in trade and other payables | ( | 544 | 500 | ||
(1,491) | (4,591) | ||||
Interest paid | ( | ( | (986) | (738) | |
Net cash flows from operating activities | (2,477) | (5,329) |
Cash flows from investing activities | |||||
Acquisitions of tangible fixed assets | 5 | ( | ( | - | - |
Acquisitions of intangible fixed assets | 8 | ( | (51) | - | |
Acquisition of subsidiaries | 7 | - | - | ||
Disposal of subsidiaries | 7 | - | - | ||
Proceeds from sale of subsidiary | 30 | - | - | ||
Sale of tangible fixed assets | 28 | ( | - | - | |
Grants related to assets received from NMA | 18 | - | - | ||
Dividends received from subsidiaries | 26 | - | - | ||
Loans repaid | - | - | |||
Loans granted | - | - | |||
Net cash flows from investing activities | ( | ( | (51) | - | |
Cash flows from financing activities | |||||
Bonds | 16 | ( | - | - | |
Repayment of financial debts from credit institutions | 16 | ( | ( | (24) | (648) |
Receipt of financial debts from credit institutions | 16 | - | 6,136 | ||
Receipt of payments under supplier financing agreement | - | - | |||
Payments to financial institutions under supplier financing agreement | ( | - | - | ||
Receipt of other loans | 16 | 2,728 | - | ||
Repayment of other loans | 16 | ( | ( | - | - |
Rent payments | 17 | ( | ( | (177) | (166) |
Net cash flows from financing activities | ( | ( | 2,527 | 5,322 | |
Net increase (decrease) in cash and cash equivalents | ( | ( | (1) | (7) | |
Cash and cash equivalents at the beginning of the period | 3 | 10 | |||
Cash and cash equivalents at the end of the period | 2 | 3 |
| plans for the technologies under development due to uncertainty, the Group assessed the technical equipment created as part of the development using the comparable market price |
| method (comparing equipment of similar capacity with market prices). The determined value was recognized as property as it is used in the Company’s operations. The remaining portion |